Covered recipient · General Payments record
MARCU MACAGBA
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$549.18
- Reported across 29 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $300.30 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $64.70 | 3 |
| PFIZER INC. | $57.00 | 3 |
| Amgen Inc. | $52.30 | 3 |
| Novo Nordisk AS | $31.88 | 2 |
| Phathom Pharmaceuticals, Inc. | $22.58 | 1 |
| Lilly USA, LLC | $20.79 | 1 |
| Lundbeck LLC | $18.56 | 1 |
| Acerta Pharma LLC | $17.12 | 1 |
| Corcept Therapeutics | $15.37 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.68 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107571330 | CMS |
| ABBVIE INC. | $17.80 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107571332 | CMS |
| ABBVIE INC. | $25.22 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107571334 | CMS |
| Amgen Inc. | $22.46 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117616218 | CMS |
| Amgen Inc. | $16.30 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117616220 | CMS |
| Amgen Inc. | $13.54 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117616222 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.12 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105393888 | CMS |
| Corcept Therapeutics | $15.37 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117779351 | CMS |
| Lilly USA, LLC | $20.79 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135754909 | CMS |
| Lundbeck LLC | $18.56 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146054427 | CMS |
| Novo Nordisk Inc | $15.94 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100342300 | CMS |
| Novo Nordisk Inc | $15.94 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100569450 | CMS |
| PFIZER INC. | $16.04 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131540922 | CMS |
| PFIZER INC. | $14.74 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131580188 | CMS |
| PFIZER INC. | $26.22 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131666672 | CMS |
| Phathom Pharmaceuticals, Inc. | $22.58 | 04/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151185014 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2021 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.